Competitive Advantage of PSMA Theranostics in Prostate Cancer-Reference-Cited by-同舟云学术

Competitive Advantage of PSMA Theranostics in Prostate Cancer

Published:2021-05 Issue:2 Volume:299 Page:261-263
ISSN:0033-8419
Container-title:Radiology
language:en
Short-container-title:Radiology

Author:

Jadvar Hossein¹^ORCID

Affiliation:

1. From the Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, 2250 Alcazar St, CSC 102, Los Angeles, CA 90033.

Funder

National Institutes of Health

Publisher

Radiological Society of North America (RSNA)

Subject

Radiology Nuclear Medicine and imaging

Link

http://pubs.rsna.org/doi/pdf/10.1148/radiol.2021210348

Reference29 articles.

1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

2. Financial toxicity associated with treatment of localized prostate cancer

3. PSMA PET: Transformational Change in Prostate Cancer Management?

4. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?

5. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical practice in prostate PET imaging;Therapeutic Advances in Medical Oncology;2023-01

2. Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer;PET Clinics;2022-07

3. Atypical Metastases in the Abdomen and Pelvis From Biochemically Recurrent Prostate Cancer: 11C-Choline PET/CT With Multimodality Correlation;American Journal of Roentgenology;2022-01